When does the trabectedin (Yondelis) patent expire?
Public patent timelines for trabectedin depend on the specific country and the exact patent family covering the drug (original approval, formulations, and any later “evergreening” claims). Patent expiry for a branded product like Yondelis is therefore not a single date globally, but a set of dates by jurisdiction.
What determines the “expiry” date you’ll see for trabectedin?
Drug market exclusivity can end through multiple mechanisms, and they don’t always line up:
- Patent expiry ends the enforceable protection of a specific patent claim.
- Regulatory exclusivities (data/market protection under medicines law) can extend market protection even after some patents expire.
- Product changes (for example, new formulations or combinations) can be covered by additional patents, creating later end dates.
So you may see different “expiry” dates depending on whether a source is talking about patent claims only or also regulatory exclusivity.
Which patent families are typically relevant for trabectedin?
For oncology products like trabectedin, the practical end of exclusivity usually involves the last long-lived items in the relevant patent set, which can include:
- Composition-of-matter patents tied to the active ingredient.
- Manufacturing/process patents.
- Formulation or dosing-form patents.
- Patents covering specific indications or combinations (if separately claimed).
Can generics or biosimilars launch right after patent expiry?
Trabectedin is a small-molecule anticancer drug, so “biosimilar” generally is not the next step. The key question is whether generic manufacturers can file/launch based on:
- Patent status in the target country.
- Whether any remaining patents block launch.
- Regulatory requirements for generic approval and whether they depend on exclusivity periods.
How to get the exact expiry date for your country
To pinpoint the real expiry date for “trabectedin patent expiry,” you need:
1. The country (US, EU/UK, Canada, etc.).
2. The product name used there (e.g., Yondelis).
3. The patent family listed for that market (not just the drug name).
4. Whether the date you want is “last patent expiry” or “regulatory exclusivity end.”
If you tell me the country (and whether you mean EU/UK or a specific member state), I can narrow the answer to the relevant timeline format used there and what “expiry” typically refers to.
Sources
No sources were provided with your question, so I can’t cite exact trabectedin patent expiry dates yet. If you share the country or a link/source you’re using, I can help interpret it precisely.